Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Change in Account Payables (2016 - 2025)

CorMedix's Change in Account Payables history spans 12 years, with the latest figure at -$7.3 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 2033.02% year-over-year to -$7.3 million; the TTM value through Dec 2025 reached $3.3 million, up 230.04%, while the annual FY2025 figure was $3.3 million, 230.04% up from the prior year.
  • Change in Account Payables for Q4 2025 was -$7.3 million at CorMedix, down from $6.5 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $6.5 million in Q3 2025 and bottomed at -$7.3 million in Q4 2025.
  • The 4-year median for Change in Account Payables is $294400.5 (2024), against an average of $44817.1.
  • The largest YoY upside for Change in Account Payables was 648.76% in 2025 against a maximum downside of 2033.02% in 2025.
  • A 4-year view of Change in Account Payables shows it stood at $434753.0 in 2022, then tumbled by 273.8% to -$755582.0 in 2023, then skyrocketed by 149.74% to $375851.0 in 2024, then tumbled by 2033.02% to -$7.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Change in Account Payables are -$7.3 million (Q4 2025), $6.5 million (Q3 2025), and $3.9 million (Q2 2025).